Evidence map›Paper›PMID 30682816›Full record

ArticleBiomolecules2019

Clinical Significance of Serum Membrane-Bound Mucin-2 Levels in Breast Cancer.

Suleyman Bademler, Alisan Zirtiloglu, Murat Sari, Muhammed Zubeyr Ucuncu, Elif Bilgin Dogru, Senem Karabulut

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A Purified Aspartic Protease fromInternational journal of molecular sciences · 2019
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Suleyman BademlerDepartment of Surgery, Institute of Oncology, Istanbul University, 34093 Istanbul, Turkey. sbademler@gmail.com.
Alisan ZirtilogluDepartment of Medical Oncology, Bakırkoy Dr Sadi Konuk Education and Research Hospital, 34147 Istanbul, Turkey. zalisan@gmail.com.ORCID 0000-0002-3319-3983
Murat SariDepartment of Medical Oncology, Institute of Oncology, Istanbul University, 34093 Istanbul, Turkey. drmuratsari@gmail.com.ORCID 0000-0003-0596-1559
Muhammed Zubeyr UcuncuDepartment of Health Science Institute, Istanbul Gelisim University, 34310 Istanbul, Turkey. muhammeducuncu@gmail.com.
Elif Bilgin DogruDepartment of Basic Oncology, Institute of Oncology, Istanbul University, 34093 Istanbul, Turkey. elifbilgin85@gmail.com.ORCID 0000-0003-0077-7939
Senem KarabulutDepartment of Medical Oncology, Institute of Oncology, Istanbul University, 34093 Istanbul, Turkey. drsenemkarabulut@gmail.com.
Istanbul University · TRBakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi · TRİstanbul Gelişim Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study was conducted to investigate the serum levels of membrane-bound mucin 2 (MUC2) in breast cancer (BC) patients and the relationship with tumour progression and known prognostic parameters. We enrolled 127 female patients with histopathologically diagnosed BC who did not receive chemotherapy (CT) or radiotherapy. Serum

Indexed as

AdultAgedBiomarkers, TumorBreast NeoplasmsCell MembraneFemaleHumansMiddle AgedMucin-2Biomarkers, TumorMUC2 protein, humanMucin-2breast cancerdiagnosticMUC2serum

Identifiers

PMID30682816
PMCPMC6406351
OpenAlexW2914777653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.